Estrogen receptors in mitochondrial metabolism: age-related changes and implications for pregnancy complications.

Estrogen hormones are primarily associated with their role as female sex hormones responsible for primary and secondary sexual development. Estrogen receptors are known to undergo age-dependent decreases due to age-related changes in hormone production. In the mitochondria, estrogen functions by reducing the production of reactive oxygen species in the electron transport chain, inhibiting apoptosis, and regulating mitochondrial DNA content.

Impact of Preoperative Sarcopenia on Survival and Postoperative Outcomes in Esophageal Cancer Patients Undergoing Esophagectomy: A Single-Center Retrospective Study.

Background Sarcopenia is the progressive and generalized loss of skeletal muscle and its associated function. Whilst it is typically associated with advanced age, it is also prevalent in patients with chronic diseases including cancer. Patients with esophageal cancer are at high risk of developing malnutrition and sarcopenia due to impaired oral intake, the effects of neoadjuvant treatment, and cancer-related cachexia.

Tissue-specific modulation of NADH consumption as an anti-aging intervention in Drosophila.

Aging is characterized by extensive metabolic dysregulation. Redox coenzyme nicotinamide adenine dinucleotide (NAD) can exist in oxidized (NAD) or reduced (NADH) states, which together form a key NADH/NAD redox pair. Total levels of NAD decline with age in a tissue-specific manner, thereby playing a significant role in the aging process.

Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.

Background: Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without baseline resistance testing raises concerns about the potential presence of pretreatment lamivudine resistance. We aimed to evaluate the efficacy of dolutegravir plus lamivudine in the absence of information on baseline resistance testing in treatment-naive people with HIV.

Methods: We did an open-label, non-inferiority, single-centre, phase 4, randomised controlled study (D2ARLING), designed to assess the efficacy and safety of dolutegravir plus lamivudine in treatment-naive people with HIV with no available baseline resistance testing.